36
https://pubmed.ncbi.nlm.nih.gov/38116864
The study found that baricitinib showed favorable clinical efficacy and safety in treating moderate-to-severe alopecia areata over a 24-week period.
“Baricitinib’s Favorable Efficacy and Safety in Moderate-to-Severe Alopecia Areata Treatment over 24 Weeks: A Study”
